The french-fry maker replaced its chief executive and [slashed guidance again]( ...

Health-care companies fell amid ongoing concerns about a backlash against the industry. The SPDR Select Sector Health Care exchange-traded fund, which tracks the health-care industry group of the S&P ...

Key Takeaways The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's ...

As a result of these uncertainties and the ambiguous benefit/risk profile of suzetrigine in LSR, the stock rating for Vertex has been downgraded to Perform from Outperform at Oppenheimer. The price ...

Oppenheimer has downgraded Vertex (NASDAQ:VRTX) to perform from outperform and removed its price target, citing mixed Phase 2 ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbar ...

The company’s suzetrigine is one of the most-watched medicines across all the drug pipelines in the biotech sector.

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...